Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals
Executive Summary
"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth
You may also be interested in...
Troubled Biotechs: Orexigen, Telik, Trubion
Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.
Impax Labs To Market Pristiq To Neurologists, Implementing Earlier Deal With Wyeth
Co-promotion deal will assist Impax in ramping up its commercial team ahead of the launch of its own branded specialty drugs.
Nektar Starts Major Push In Opioid-Induced Constipation Space
Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters